{"id":"NCT01313221","sponsor":"Amgen","briefTitle":"Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis","officialTitle":"A Randomized, Blinded Assessor Study to Evaluate the Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent Versus Etanercept 50 mg Twice Weekly in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04","primaryCompletion":"2012-12","completion":"2013-05","firstPosted":"2011-03-11","resultsPosted":"2014-05-02","lastUpdate":"2017-03-15"},"enrollment":310,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"etanercept","otherNames":["Enbrel"]},{"type":"DRUG","name":"Topical agents","otherNames":[]}],"arms":[{"label":"Etanercept 50 mg BIW","type":"ACTIVE_COMPARATOR"},{"label":"Etanercept 50 mg QW + Topical","type":"EXPERIMENTAL"}],"summary":"To estimate the difference in effectiveness between treatment with etanercept 50 mg twice weekly (BIW) and treatment with etanercept 50 mg once weekly (QW) plus an as needed (PRN) topical agent for 12 weeks in adults with moderate to severe plaque psoriasis.","primaryOutcome":{"measure":"Percent Change in Psoriasis Area and Severity Index (PASI) From Week 12 to Week 24","timeFrame":"Week 12 and Week 24","effectByArm":[{"arm":"Etanercept 50 mg BIW","deltaMin":17.02,"sd":7.06},{"arm":"Etanercept 50 mg QW + Topical","deltaMin":0.86,"sd":7.06}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":24,"countries":["Canada"]},"refs":{"pmids":["25611084","24980988","26330052"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":177},"commonTop":["Nasopharyngitis","Injection site reaction","Headache","Upper respiratory tract infection","Injection site erythema"]}}